Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (NCT04910022)

🧪 Interventions in This Study

• NMS-03305293 (DRUG)
• Temozolomide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (18 Sites)

• Mayo Clinic Hospital - Phoenix — Phoenix, Arizona
• University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center — Orange, California
• Mayo Clinic Florida — Jacksonville, Florida
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Mayo Clinic Cancer Center — Rochester, Minnesota
• Memorial Sloan-Kettering Cancer Center — New York, New York
• UT Southwestern Medical Center — Dallas, Texas
• The University of Texas MD Anderson Cancer Center — Houston, Texas
• University of Utah, University Hospital — Salt Lake City, Utah
• University of Virginia Health System — Charlottesville, Virginia
• Swedish Medical Center - First Hill Campus — Seattle, Washington
• IRCCS Istituto delle Scienze Neurologiche di Bologna — Bologna,
• IRCCS Istituto Neurologico Carlo Besta — Milan,
• Istituto Oncologico Veneto - IRCCS — Padova,
• Istituto Clinico Humanitas — Rozzano,
• Erasmus Medical Center — Rotterdam,
• PanOncology Trials (Pan American Center for Oncology Trials, LLC) — Rio Piedras,
• University Hospital Zurich — Zurich,

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Glioblastoma

• Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma — Milwaukee, Wisconsin
• A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. — New York, New York
• A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors — San Francisco, California
• Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma — Phoenix, Arizona
• A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma — Birmingham, Alabama
• Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma — Fairbanks, Alaska

Explore by condition: All Glioblastoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.